OPNT News and Press, Opiant Pharmaceuticals Inc. From 03/15/22

Opiant Pharmaceuticals press release (NASDAQ:OPNT): Q4 GAAP EPS of $0.11 beats by $0.01. Revenue of $13.8M (+39.1% Y/Y) beats by $0.54M. For further details see: Opiant Pharmaceuticals GAAP EPS of $0.11 beats by $0.01, revenue of $13.8M beats by $0.54M

Opiant Pharmaceuticals (NASDAQ:OPNT) is scheduled to announce Q4 earnings results on Tuesday, Mar. 15, after market close. The consensus EPS estimate is $0.10 and the consensus revenue estimate is $13.26M (+32.6% Y/Y).  Over the last 2 years, OPNT has beaten EPS estimates 75% of the...

OTCPK:ANCUF, ATHX, CAL, CHMI, CLPR, FF, GOCO, HYRE, KODK, LFT, LOTZ, LX, MTN, OPNT, S, SFT, SMAR, SRG, SRGA, TCON, YALA, YY, ZDGE For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Tuesday's close

SANTA MONICA, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that its Chief Executive Officer, Dr. Roger Crystal, ...

SANTA MONICA, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report fourth quarter 2021 financial res...

SANTA MONICA, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced positive topline results from a multi-dose pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, an investigational treatment ...

Opiant Pharmaceuticals (NASDAQ:OPNT) briefly gained 1.5% after a report that the company is speculated to be a takeover target. A large rival is said to be circling the pharmaceutical company, according to a Betaville "uncooked" alert. Opiant (OPNT) didn't respond to Betaville reque...

SANTA MONICA, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (“BARDA”) for an additiona...

SANTA MONICA, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the Compensation Commi...

Shares of Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) traded today at $29.02, eclipsing its 52-week high. So far today approximately 949,000 shares have been exchanged, as compared to an average 30-day volume of 49,000 shares. Opiant Pharmaceuticals Inc is a specialty pharmaceutical compan...